SCHEMBL23978689

SCHEMBL23978689

COC(=O)c1c(Cl)cc(C(=O)NCc2cccc(Cl)c2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.55
APEX1 P27695 1/20 0.55
ROCK2 O75116 1/20 0.50
ROCK1 Q13464 1/20 0.50
MMP13 P45452 1/20 0.50
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
PLA2G1B P04054 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
CYP2C9 P11712 1/20 0.48
RAB9A P51151 1/20 0.48
THRB P10828 1/20 0.48
POLB P06746 1/20 0.47
HCRTR1 O43613 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978695 0.89 ROCK2 (0.51) NPC1ROCK2ROCK1MMP13CYP1A2
SCHEMBL23978716 0.88 MMP13 (0.68) APEX1ROCK2ROCK1MMP13CYP2D6
SCHEMBL23978773 0.88 EPHX2 (0.49) ROCK2ROCK1MMP13CYP1A2CYP2D6
SCHEMBL23978749 0.87 NPC1 (0.57) NPC1APEX1CYP1A2CYP2D6CYP2C19
SCHEMBL23978699 0.85 NPC1 (0.59) NPC1APEX1CYP1A2CYP2D6CYP2C19
SCHEMBL23978780 0.84 ROCK2 (0.51) ROCK2ROCK1MMP13RAB9AHPGD
SCHEMBL23978883 0.84 MEN1 (0.69) ROCK2ROCK1CYP1A2CYP2D6CYP2C19
SCHEMBL23979111 0.84 LMNA (0.63) APEX1MEN1KMT2AGAAHPGD
SCHEMBL30279402 0.80 NPC1 (0.50) NPC1APEX1CYP1A2CYP2D6CYP2C19
SCHEMBL5332860 0.79 NPC1 (0.72) NPC1APEX1MMP13CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
CN-115916176-A Inhibitors of alpha 2 beta 1 integrin and methods of use thereof 加利福尼亚大学董事会 2023-04-04 CN disclosed
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-29 US disclosed
WO-2021222789-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 NPC1 2492/4885APEX1 3417/4885ROCK2 485/4885
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF ITGB1, ITGB2, ITGA2 NPC1 2492/4885APEX1 3417/4885ROCK2 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.